QTRX
Quanterix Corp

1,103
Mkt Cap
$284.47M
Volume
567,295.00
52W High
$8.77
52W Low
$4.05
PE Ratio
-2.61
QTRX Fundamentals
Price
$6.09
Prev Close
$5.88
Open
$5.97
50D MA
$6.95
Beta
1.75
Avg. Volume
776,072.25
EPS (Annual)
-$1.00
P/B
0.90
Rev/Employee
$291,764.33
Loading...
Loading...
News
all
press releases
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
QTRX submits a 510(k) to the FDA for its multi-analyte blood test aimed at evaluating cognitive symptoms for possible Alzheimer's disease.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Quanterix Submits FDA 510(k) For Multi-Analyte Blood Test For Alzheimer's Disease
(RTTNews) - Quanterix Corporation (QTRX) on Tuesday said it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test to...
Nasdaq News: Markets·4d ago
News Placeholder
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimers Disease Detection
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket...
Business Wire·4d ago
News Placeholder
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimers Risk Profiling
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the...
Business Wire·17d ago
News Placeholder
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on...
Business Wire·22d ago
News Placeholder
Quanterix Corporation (NASDAQ:QTRX) Given Consensus Recommendation of "Hold" by Analysts
Shares of Quanterix Corporation (NASDAQ:QTRX - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat.com reports...
MarketBeat·1mo ago
News Placeholder
Quanterix (NASDAQ:QTRX) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Quanterix from a "sell" rating to a "hold" rating in a research report on Monday...
MarketBeat·1mo ago
News Placeholder
Quanterix (NASDAQ:QTRX) Given New $8.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group boosted their price target on Quanterix from $5.00 to $8.00 and gave the stock a "hold" rating in a report on Monday...
MarketBeat·2mo ago
News Placeholder
Quanterix Announces Landmark Nature Study Redefining Alzheimers Disease Neuropathology Prevalence
Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the...
Business Wire·2mo ago
News Placeholder
Quanterix (NASDAQ:QTRX) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·2mo ago
<
1
2
...
>

Latest QTRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.